%0 Journal Article
%T Asian Case of Metastatic Melanoma in Which a Complete Response Was Maintained after Discontinuation of Dabrafenib and Trametinib
%A Rikako Deno
%A Atsushi Tanemura
%A Madoka Takafuji
%A Yuma Hanaoka
%A Eiji Kiyohara
%A Noriko Arase
%A Mari Wataya-Kaneda
%A Manabu Fujimoto
%J Journal of Cosmetics, Dermatological Sciences and Applications
%P 55-58
%@ 2161-4512
%D 2020
%I Scientific Research Publishing
%R 10.4236/jcdsa.2020.102006
%X A 54-year-old man diagnosed with metastatic melanoma of the right inguinal node with occult primary developed liver and bone metastases. The combination of dabrafenib plus trametinib was initiated, and a complete response (CR) was achieved 24 months after starting treatment. One month later, the target therapy was discontinued at the patient¡¯s decision, and he has remained free from progression for 21 months since discontinuation. To the extent of our knowledge, real-world data in Asian melanoma concerning the discontinuation of dabrafenib plus trametinib after achieving CR have not been published; therefore, our case is a meaningful one for considering to cease target drugs and to rescue their financial toxicity.
%K Metastatic Melanoma
%K Dabrafenib
%K Trametinib
%K Complete Response
%K Discontinuation
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=99250